Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

D Gelber

Showing results (181-190 of 395) with videos related to

Pageof 40
Sort By:
Cancer|December 22, 2005
Ocular toxicity during adjuvant chemoendocrine therapy for early breast cancer: results from International Breast Cancer Study Group trialsLorenzo Gianni, Ilaria Panzini, Sigui Li, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 27, 2003
Childhood T-cell acute lymphoblastic leukemia: the Dana-Farber Cancer Institute acute lymphoblastic leukemia consortium experienceJohn M Goldberg, Lewis B Silverman, Donna E Levy, et al.
Breast Cancer Research and Treatment|March 13, 2009
Prognostic and predictive impact of central necrosis and fibrosis in early breast cancer: results from two International Breast Cancer Study Group randomized trials of chemoendocrine adjuvant therapyEugenio Maiorano, Meredith M Regan, Giuseppe Viale, et al.
Cancer|July 10, 2001
Excellent therapeutic efficacy and minimal late neurotoxicity in children treated with 18 grays of cranial radiation therapy for high-risk acute lymphoblastic leukemia: a 7-year follow-up study of the Dana-Farber Cancer Institute Consortium Protocol 87-01D P Waber, B L Shapiro, S C Carpentieri, et al.
The New England Journal of Medicine|June 29, 1995
Female sex and higher drug dose as risk factors for late cardiotoxic effects of doxorubicin therapy for childhood cancerS E Lipshultz, S R Lipsitz, S M Mone, et al.
Lancet (London, England)|January 8, 2008
Adjuvant chemotherapy in oestrogen-receptor-poor breast cancer: patient-level meta-analysis of randomised trials, M Clarke, A S Coates, et al.
Medical Care|March 1, 1996
Responsiveness of a single-item indicator versus a multi-item scale: assessment of emotional well-being in an international adjuvant breast cancer trialC Hürny, J Bernhard, A Coates, et al.
Lancet (London, England)|April 20, 1996
Adjuvant chemotherapy plus tamoxifen compared with tamoxifen alone for postmenopausal breast cancer: meta-analysis of quality-adjusted survivalR D Gelber, B F Cole, A Goldhirsch, et al.
BMC Infectious Diseases|June 23, 2007
Characteristics and management of HIV-1-infected pregnant women enrolled in a randomised trial: differences between Europe and the USAMarie-Louise Newell, Sharon Huang, Simona Fiore, et al.
The Journal of Infectious Diseases|July 23, 2002
Development of resistance mutations in women receiving standard antiretroviral therapy who received intrapartum nevirapine to prevent perinatal human immunodeficiency virus type 1 transmission: a substudy of pediatric AIDS clinical trials group protocol 316Coleen K Cunningham, Marie-Laure Chaix, Claire Rekacewicz, et al.
Pageof 40

Showing results (181-190 of 395) with videos related to

Sort By:
Pageof 40
Cancer|December 22, 2005
Ocular toxicity during adjuvant chemoendocrine therapy for early breast cancer: results from International Breast Cancer Study Group trialsLorenzo Gianni, Ilaria Panzini, Sigui Li, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 27, 2003
Childhood T-cell acute lymphoblastic leukemia: the Dana-Farber Cancer Institute acute lymphoblastic leukemia consortium experienceJohn M Goldberg, Lewis B Silverman, Donna E Levy, et al.
Breast Cancer Research and Treatment|March 13, 2009
Prognostic and predictive impact of central necrosis and fibrosis in early breast cancer: results from two International Breast Cancer Study Group randomized trials of chemoendocrine adjuvant therapyEugenio Maiorano, Meredith M Regan, Giuseppe Viale, et al.
Cancer|July 10, 2001
Excellent therapeutic efficacy and minimal late neurotoxicity in children treated with 18 grays of cranial radiation therapy for high-risk acute lymphoblastic leukemia: a 7-year follow-up study of the Dana-Farber Cancer Institute Consortium Protocol 87-01D P Waber, B L Shapiro, S C Carpentieri, et al.
The New England Journal of Medicine|June 29, 1995
Female sex and higher drug dose as risk factors for late cardiotoxic effects of doxorubicin therapy for childhood cancerS E Lipshultz, S R Lipsitz, S M Mone, et al.
Lancet (London, England)|January 8, 2008
Adjuvant chemotherapy in oestrogen-receptor-poor breast cancer: patient-level meta-analysis of randomised trials, M Clarke, A S Coates, et al.
Medical Care|March 1, 1996
Responsiveness of a single-item indicator versus a multi-item scale: assessment of emotional well-being in an international adjuvant breast cancer trialC Hürny, J Bernhard, A Coates, et al.
Lancet (London, England)|April 20, 1996
Adjuvant chemotherapy plus tamoxifen compared with tamoxifen alone for postmenopausal breast cancer: meta-analysis of quality-adjusted survivalR D Gelber, B F Cole, A Goldhirsch, et al.
BMC Infectious Diseases|June 23, 2007
Characteristics and management of HIV-1-infected pregnant women enrolled in a randomised trial: differences between Europe and the USAMarie-Louise Newell, Sharon Huang, Simona Fiore, et al.
The Journal of Infectious Diseases|July 23, 2002
Development of resistance mutations in women receiving standard antiretroviral therapy who received intrapartum nevirapine to prevent perinatal human immunodeficiency virus type 1 transmission: a substudy of pediatric AIDS clinical trials group protocol 316Coleen K Cunningham, Marie-Laure Chaix, Claire Rekacewicz, et al.
Pageof 40